Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ViatrisFRA:VIA -5.39%64 EV-to-EBITDA is 11.93 as of Aug. 09, 2026, which is 32% above its 10-year median of 9.02. GuruFocus rates FRA:VIA with a GF Score™ of 64/100 and a GF Value™ of €10.15 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 737 Drug Manufacturers companies, Viatris ranks better than 55.77% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Viatris's enterprise value is €26,875 Mil.
Viatris's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €2,253 Mil. Therefore, Viatris's EV-to-EBITDA for today is 11.93.
The historical rank and industry rank for Viatris's EV-to-EBITDA or its related term are showing as below:
FRA:VIA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -79.76 Med: 9.02 Max: 20.64
Current: 11.81
During the past 13 years, the highest EV-to-EBITDA of Viatris was 20.64. The lowest was -79.76. And the median was 9.02.
FRA:VIA's EV-to-EBITDA is ranked better than 55.77% of 737
companies
in the Drug Manufacturers industry
Industry Median: 13.28
vs FRA:VIA: 11.81
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-08-09), Viatris's stock price is €14.00.
Viatris's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.307. Therefore, Viatris's PE Ratio (TTM) for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Viatris's share price for today is €14.00.
Viatris's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.307.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Viatris's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VIA vs UTHR, NBIX, ELAN: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viatris's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Viatris's EV-to-EBITDA falls into.
Viatris's current Enterprise Value is €26,875 Mil.
Viatris's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2,253 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viatris (FRA:VIA) has a EV-to-EBITDA of 11.93 as of Aug. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Viatris. This is 32% above median its historical median of 9.02. According to the industry distribution chart, Viatris ranks #326 out of 737 companies in the Drug Manufacturers industry, placing it in the top 44.2%.
Is Viatris' EV-to-EBITDA too high?
Viatris' current EV-to-EBITDA of 11.93 is 32% above median its 10-year median of 9.02. The Drug Manufacturers industry median EV-to-EBITDA is 13.28. Viatris' value of 11.93 is 10.2% below this industry median. Based on the distribution chart, Viatris ranks #326 out of 737 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Viatris has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viatris' EV-to-EBITDA compare to UTHR and NBIX?
According to the Drug Manufacturers industry distribution chart, Viatris ranks #326 out of 737 companies for EV-to-EBITDA. This puts Viatris in the upper half of its industry. The industry median EV-to-EBITDA is 13.28. Viatris' value of 11.93 is 10.2% below this benchmark. While the company's 10-year median is 9.02 vs. the industry median of 13.28, Viatris has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.28, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viatris's current EV-to-EBITDA of 11.93 is 10.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Viatris. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viatris's current EV-to-EBITDA is 11.93, which is 32% above median its own 10-year median of 9.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Based on GuruFocus' analysis, Viatris (FRA:VIA) is currently considered Significantly Overvalued. The stock's GF Value™ is €10.15, compared to a current price of €14.00 — trading 37.9% above its estimated fair value. The current EV-to-EBITDA is 11.93, which is 32% above median its 10-year median of 9.02 and 10.2% below the Drug Manufacturers industry median of 13.28. Viatris' overall GF Score™ is 64/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Viatris (FRA:VIA), the current EV-to-EBITDA is 11.93 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viatris (FRA:VIA) Overvalued in 2026?
Based on GuruFocus' analysis, Viatris stock appears to be overvalued.
The current stock price of €14.00 is trading 37.9% above its estimated GF Value™ of €10.15.
GuruFocus considers Viatris to be Significantly Overvalued.
Key valuation signals for FRA:VIA:
EV-to-EBITDA: 11.93 (32% above median its 10-year median of 9.02)
GF Value™: €10.15 vs. price of €14.00 (37.9% above fair value)
Industry Position: 10.2% below the Drug Manufacturers median (#326 of 737)
No single metric tells the full story. See the FRA:VIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
64GF Score
Get the complete analysis for FRA:VIA
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VIA has been successfully added to your 
